Philipp Erben

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Jörge E. Cortes, Philippe Rousselot, Dong‐Wook Kim et al. · Blood · 2006 · 418 citations

Medicine, Hematology, Oncology +16

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 417 citations

Life Sciences, Molecular Biology, Oncology +16

Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Timothy P. Hughes, Giuseppe Saglio, Susan Branford et al. · Journal of Clinical Oncology · 2009 · 309 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +14

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Martin C. Müller, Jörge E. Cortes, Dong‐Wook Kim et al. · Blood · 2009 · 286 citations · Full text

Medicine, Hematology, Oncology +10

Comprehensive mutational profiling in advanced systemic mastocytosis

Juliana Schwaab, Susanne Schnittger, Karl Sotlar et al. · Blood · 2013 · 258 citations

Life Sciences, Genetics, Molecular Genetics +14